Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: Nonsteroidal anti-inflammatory drugs (NSAIDs) increase the risk of peptic ulcer disease by 5- to 7-fold in the first 3 months of treatment. This study examined the relative cost-effectiveness of different strategies for the primary prevention of NSAID-induced ulcers in patients that are starting NSAID treatment.
MEASUREMENTS AND MAIN RESULTS: A decision analysis model was developed to compare the cost-effectiveness of 6 prophylactic strategies relative to no prophylaxis for patients 65 years of age starting a 3-month course of NSAIDs: (1) testing for Helicobacter pylori infection and treating those with positive tests; (2) empiric treatment of all patients for Helicobacter pylori; (3) conventional-dose histamine2 receptor antagonists; (4) high-dose histamine2 receptor antagonists; (5) misoprostol; and (6) omeprazole. Costs were estimated from 1997 Medicare reimbursement schedules and the Drug Topics Red Book. Empiric treatment of Helicobacter pylori with bismuth, metronidazole, and tetracycline was cost-saving in the baseline analysis. Selective treatment of Helicobacter pylori, misoprostol, omeprazole, and conventional-dose or high-dose histamine2 receptor antagonists cost $23,800, $46,100, $34,400, and $15,600 or $21,500 per year of life saved, respectively, relative to prophylaxis. The results were sensitive to the probability of an ulcer, the probability and mortality of ulcer complications, and the cost of, efficacy of, and compliance with prophylaxis. The cost-effectiveness estimates did not change substantially when costs associated with antibiotic resistance of Helicobacter pylori were incorporated.
CONCLUSIONS: Several strategies for primary prevention of NSAID-induced ulcers in patients starting NSAIDs were estimated to have acceptable cost-effectiveness relative to prophylaxis. Empirically treating all patients for Helicobacter pylori with bismuth, metronidazole, and tetracycline was projected to be cost-saving in older patients.
- Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 1989;96:647–55.
- Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888–99. CrossRef
- Bjorkman DJ, Kimmey MB. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment, and prevention. Drg Dis. 1995;13:119–29.
- Larkai EN, Lacey Smith J, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989;11:158–62. CrossRef
- Langman MJS. Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use. Gastroenterology. 1989;96:640–6.
- Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527–32.
- Lockard OO, Evey KJ, Butt JH, Silvoso GR, Sisk C, Holt S. The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc. 1980;26:5–7.
- Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med. 1979;91:517–20.
- Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213–22. CrossRef
- Elliott SL, Yeomans ND, Buchanan RRC, Smallwood RA. Efficacy of 12 month’s misoprostol as prophylaxis against NSAID-induced gastric ulcers. Scand J Rheumatol. 1994;23:171–6.
- Graham DY, White RJ, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med. 1993;119:257–62.
- Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflamatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344–50.
- Silverstein FE, Draham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatologic arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–9.
- Raskin JB, White RH, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol. 1996;91:223–7.
- Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 1988;297:1017–21.
- Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1993;153:2449–54. CrossRef
- Robinson M, Mills RJ, Euler AR. Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy. Aliment Pharmacol Ther. 1991;5:143–50. CrossRef
- Roth SJ, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med. 1987;147:1798–1801. CrossRef
- Simon B, Muller P. Nizatidine in therapy and prevention of non-steroidal anti-inflammatory drug-induced gastroduodenal ulcer in rheumatic patients. Scand J Gastroenterol. 1994;29(suppl 206):25–8.
- Taha AS, Hudson M, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996;334:1435–9. CrossRef
- Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users. Gastroenterology. 1996;110(4):A86. Abstract.
- Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. Scand J Gastroenterol. 1996;31:753–8.
- Chan FKL, Sung JJY, Chaung SCS, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drugs therapy to prevent peptic ulcers. Lancet. 1997;350:975–9. CrossRef
- Li EKM, Sung JJY, Suen R, et al. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of nonsteroidal anti-inflammatory drugs. Scand J Rheumatol. 1996;25:42–6.
- Gabriel SE, Jaakkimainen L, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum. 1993;36:447–59. CrossRef
- Gabriel SE, Campion ME, O’Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1994;37:333–41. CrossRef
- Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061–5. CrossRef
- Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care. 1992;8:234–44. CrossRef
- Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41–7. CrossRef
- Maetzel A, Ferraz MG, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1998;41:16–25. CrossRef
- Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving nonsteroidal anti-inflammatory drugs. Postgrad Med J. 1990;66:639–44.
- Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:82–123.
- Tamblyn R, Berkson L, Dauphinee WD, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med. 1997;127:429–38.
- Medicare RBRVS: The Physician’s Guide. 4th ed. Chicago, Ill: American Medical Association; 1997.
- Current Procedural Terminology 1997. 4th ed. Chicago, Ill: American Medical Association; 1997.
- Health Care Financing Agency. Medicare Provider Analysis and Review (MEDPAR) File. Washington, DC: US Government Press; 1997.
- Drug Topics Red Book. Montvale, NJ: Medical Economics Company; 1997.
- Megraud F. How should Helicobacter pylori infection be diagnosed? Gastroenterology. 1997;113:S93-S98.
- Health Care Financing Agency. Clinical Diagnostic Laboratory Fee Schedule. Washington, DC: U.S Government Press; 1997.
- Bianchi Porro G, Lazzaroni M, Petrillo M. Double-blind, double-dummy endoscopic comparison of the mucosal protective effects of misoprostol versus ranitidine on naproxen-induced mucosal injury to the stomach and duodenum in rheumatic patients. Am J Gastroenterol. 1997;92:663–7.
- Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277–80. CrossRef
- Pounder R. Silent peptic ulceration: deadly silence or golden silence? Gastroenterology. 1989;96:626–31.
- Elashoff JD, Van Deventer G, Reedy TJ, et al. Long-term follow-up of duodenal ulcer patients. J Clin Gastroenterol. 1983;5:509–15. CrossRef
- Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102:493–6.
- Chiba N. Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Am J Gastroenterol. 1996;91:2139–43.
- Adamek RJ, Bethke TD, for the International Pantoprazole HP Study Group. Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. Am J Gastroenterol. 1998;93:1919–24. CrossRef
- Chu KM, Choi HK, Tuen HH, Law SY, Branicki FJ, Wong J. A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori. Am J Gastroenterol. 1998;93:1436–42. CrossRef
- Graham DY, Malaty HM, Evans DG, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States: effect of age, race, and socioeconomic status. Gastroenterology. 1991;100:1495–1501.
- Graham DY, Klein PD, Opekum AR, Boutton TW. Effect of age on the frequency of active Campylobacter pylori infection diagnosis by the [13C] urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis. 1988;157:777–80.
- Cutler AF, Havstad S, Ma CK, Blaser MJ, Perez-Perez GI, Schubert TT. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology. 1995;109:136–41. CrossRef
- Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology. 1997;113:S131-S148.
- Malfertheiner P. Compliance, adverse events, and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol. 1993;28(suppl 196):34–7.
- Taylor JL, Zagari M, Murphy K, Freston JW. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med. 1997;157:87–97. CrossRef
- Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539–45.
- Hamby LS, Zweng TN, Strodel WE. Perforated gastric and duodenal ulcer: an analysis of prognostic factors. Ann Surg. 1993;59:319–23.
- Boey J, Choi SK, Poon A, Algaratnam TT. Risk stratification in perforated duodenal ulcers: a prospective validation of risk factors. Ann Surg. 1987;205:22–6. CrossRef
- Silverstein FE, Gilbert DA, Tedesco FJ, Buenger MK, Persing J. The national ASGE survey on upper gastrointestinal bleeding, II: clinical prognostic factors. Gastrointest Endosc. 1981;27:80–93. CrossRef
- Statistical Abstract of the United States. 117th ed. Washington, DC: US Bureau of the Census; 1997.
- Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996:214–46.
- Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull. 1998;54(1):207–16.
- Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91. CrossRef
- Kovar PA, Allegrant JP, MacKenzie CR, Peterson MG, Gutin B, Charlson ME. Supervised fitness walking in patients with osteoarthritis of the knee: a randomized controlled trial. Ann Intern Med. 1992;116:529–34.
- Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol. 1996;91:2080–6.
- Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet. 1998;352:1016–21. CrossRef
- Guess HA, West R, Strand LM, et al. Fatal upper gastrointestinal hemorrhage or perforation among users and nonusers of nonsteroidal anti-inflammatory drugs in Saskatchewan, Canada 1983. J Clin Epidemiol. 1988;41:35–45. CrossRef
- Moller Hansen J, Hallas H, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision making. Scand J Gastroenterol. 1996;31:126–30.
- Fendrick AM, Bandekar RR, Chernew ME, Scheiman JM. Should patients requiring chronic NSAID therapy be screened for H. pylori? J Gen Intern Med. 1998;13(suppl 1):31 Abstract.
- Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (Select) trial in osteoarthritis. Br J Rheumatol. 1998;37:946–51. CrossRef
- Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol. 1996;35(suppl 1):61–7.
- Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol. 1998;37:937–45. CrossRef
- Cost-effectiveness of strategies for primary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcer disease
Journal of General Internal Medicine
Volume 15, Issue 6 , pp 400-410
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- peptic ulcer disease
- Industry Sectors